Clinical Trials Sponsored by Aeris Therapeutics

Total 6488 results

Aeris Therapeutics

Terminated

A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema

Lung Diseases | Pulmonary Emphysema | Chronic Obstructive Pulmonary Disease(COPD)

Israel
Aeris Therapeutics

Terminated

Post Market Registry Study of the AeriSeal System

Pulmonary Emphysema

Germany, Israel
Aeris Therapeutics

Terminated

A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema

Emphysema | Chronic Pulmonary Obstructive Disease

Germany, Israel, Austria, France
Aeris Therapeutics

Completed

AeriSeal System for Lung Volume Reduction

Lung Diseases | Emphysema | Pulmonary Emphysema | Chronic Obstructive Pulmonary Disease (COPD)

Israel, Austria, France, Germany
Aeris Therapeutics

Completed

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Pulmonary Emphysema

United States
Aeris Therapeutics

Completed

A Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema

Advanced Emphysema

Germany
Aeris Therapeutics

Terminated

Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Pulmonary Emphysema

Netherlands
Aeris Therapeutics

Terminated

Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Pulmonary Emphysema

Israel
Aeris Therapeutics

Completed

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study

Pulmonary Emphysema

United States
Aeris Therapeutics

Terminated

Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema (CV+/-)

Pulmonary Emphysema

Germany, Israel
Aeris Therapeutics

Withdrawn

Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema

Emphysema | Chronic Obstructive Pulmonary Disease (COPD)
Aeris Therapeutics

Completed

Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study

Homogeneous Emphysema

United States
Aeris Therapeutics

Completed

Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study

Chronic Obstructive Pulmonary Disease | Pulmonary Emphysema

Israel
Aeris Therapeutics

Withdrawn

Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema

Advanced Upper Lobe Predominant Emphysema
Aeris Therapeutics

Completed

US 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study - Initial Formulation

Pulmonary Emphysema

United States
Aeris Therapeutics

Terminated

Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE) (ASPIRE)

Pulmonary Emphysema

United States, Spain, France, Israel, Netherlands, Greece, Italy
Aeris Therapeutics

Completed

US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Chronic Obstructive Pulmonary Disease | Pulmonary Emphysema

United States
Aeris Therapeutics

Completed

AeriSeal® System for Lung Volume Reduction in Patients With Advanced Emphysema

Lung Diseases | Pulmonary Emphysema | COPD

Israel
Aeras

Completed

Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US ((A-051))

Tuberculosis

United States
Aeras

Completed

A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB (C-012-402)

Tuberculosis

Kenya
Aeras

Completed

A Leukapheresis Study for Immune Responses in Healthy US Adults Who Receive BCG Vaccination Followed by Boosting With AERAS-402 (C-021-402)

Tuberculosis
Aeras

Completed

A Study to Evaluate Safety and Immunogenicity of AERAS-402

Tuberculosis

India
Aeras

Completed

Study of AERAS 422 in Healthy Adults

Tuberculosis

United States
Auris Medical AG

Completed

AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery (TRAVERS)

Vestibular Vertigo

France
Auris Medical AG

Completed

AM-101 in the Treatment of Acute Tinnitus 3 (TACTT3)

Tinnitus

Germany
Auris Medical AG

Completed

Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss

Hearing Loss

Germany
Aerin Medical

Completed

Quality of Life Impact of Chronic Rhinitis Treatment With Aerin Medical Device

Chronic Rhinitis

United States
Aerie Pharmaceuticals

Completed

A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease (COMET-1)

Dry Eye Disease

United States
Aerie Pharmaceuticals

Completed

Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open Angle Glaucoma

United Kingdom, Spain, Austria, Belgium, Czechia, France, Germany, Hungary, Italy, Latvia, Poland
Aerin Medical

Completed

Posterior Nasal Nerve (PNN) Rhinitis Study

Chronic Rhinitis

United States
Aerie Pharmaceuticals

Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Ocular Hypertension | Open Angle Glaucoma

Japan
Aerie Pharmaceuticals

Completed

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Ocular Hypertension | Glaucoma, Open-Angle

United States
Aleris Obesity

Completed

Effects of Long Biliopancreatic Limb vs. Long Alimentary Limb in Superobesity, a Randomized Study

Weight Loss | Morbid Obesity

Sweden
Aerie Pharmaceuticals

Completed

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Primary Open Angle Glaucoma or Ocular Hypertension

United States
Aerie Pharmaceuticals

Completed

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Aerin Medical

Completed

Treatment of Nasal Airway Obstruction Using the Aerin Medical Device

Nasal Obstruction

United States
GlaxoSmithKline
Aeras

Completed

Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342

Tuberculosis

Belgium
Xeris Pharmaceuticals

Completed

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

Hypoglycemia | Diabetes Mellitus, Type 1

United States, Canada
GlaxoSmithKline
Aeras

Completed

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents

Tuberculosis

South Africa
Aerie Pharmaceuticals

Completed

Study of AR-13324 in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

AR-12286 in Combination With Latanoprost

Ocular Hypertension | Glaucoma

United States
Aerie Pharmaceuticals

Completed

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

Ocular Hypertension | Open Angle Glaucoma

United States
Auris Medical AG

Completed

AM-111 in the Treatment of Acute Inner Ear Hearing Loss (HEALOS)

Hearing Loss

Bulgaria
Auris Medical AG

Completed

AM-101 in the Treatment of Post-Acute Tinnitus 2 (AMPACT2)

Tinnitus

Germany
Auris Medical AG

Completed

Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus

Tinnitus

Germany
Aleris Eye

Recruiting

Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods

Cataract

Sweden
Aerin Medical

Active, not recruiting

RhinAer Procedure for Treatment of Chronic Rhinitis Study (RHINTRAC)

Chronic Rhinitis

United States
Xeris Pharmaceuticals

Active, not recruiting

Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism

Hypothyroidism

United States
Aerie Pharmaceuticals

Completed

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

Dry Eye Disease

United States
Xeris Pharmaceuticals

Completed

Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D

Hypoglycemia

Canada

3

Subscribe